

# NEUROTHERAPEUTICS SEMINAR SERIES



TEXAS A&M HEALTH

Institute of Pharmacology  
and Neurotherapeutics

## Modulating the Microglial Response to Neurodegeneration with Novel Therapeutics

**Monday, August 29, 2022**

HSC Bryan Campus/HPEB Room LL43AB

12:00 - 1:00 PM

**Lunch Provided --- Q&A Session & Networking Opportunity**

Join via Zoom  Meeting ID: 942 5772 9124 Passcode: 052206

### Dr. Jim Ray

*Director of the MD Anderson Foundation Neurodegeneration Consortium, Houston*

Dr. Jim Ray is the director of the M.D. Anderson Foundation Neurodegeneration Consortium (NDC), a non-profit biotech-like drug discovery group that develops therapeutics for Alzheimer's and related disorders. The NDC is a collaboration among MD Anderson, Baylor College of Medicine, the MIT, and the Whitehead Institute. Dr. Ray received PhD in neuroscience from Washington University Medical School and published high-profile papers on presenilins in notch and APP proteolysis.

Dr. Ray has pursued a career in drug discovery. He worked at top pharma companies including Merck, Envoy and Takeda, and helped in advancing late-stage compounds to clinical trials for neurological indications. At MD Anderson, he is directing the NDS, which is developing innovative ways to prevent brain disease. The NDC has raised \$80M in funding. By combining the expertise of MD Anderson with other teams, the NDC is striving for clinical trials of new drugs and biomarkers for AD and neurology conditions.



**Dr. Jim Ray**

Host: Dr. Samba Reddy  
sambareddy@tamu.edu



For more information, contact Dr. Sreevidhya Ramakrishnan at [sreevidh@tamu.edu](mailto:sreevidh@tamu.edu) IPN Website: